Abbott and the American Diabetes Association® Launch First-of-Its-Kind Community Initiative in Columbus, Ohio, to Advance Access to Diabetes Care and Technology

- Abbott (NYSE: ABT) and the American Diabetes Association ® (ADA) announced today the launch of their first joint community health partnership. The community initiative, which is the first program under the ADA's Health Equity Now ™ platform 1 will launch in Columbus, Ohio and be conducted in partnership with the National Center for Urban Solutions (NCUS), a Columbus -based organization focused on providing solutions in workforce development, education and wellness. The program seeks to better understand and address healthcare disparities for people of color living with diabetes, while fostering accessibility of diabetes care technology within the community.

As part of the program, NCUS will provide up to 150 Black adults living with diabetes in the Columbus community with health education and access to Abbott's FreeStyle ® Libre flash glucose monitoring technology. By removing existing barriers to tools and technology, this program aims to demonstrate how continuous glucose monitoring can help improve diabetes management and quality of life for Black people living with diabetes in the Columbus community.

Black Americans are 60% more likely to be diagnosed with diabetes 2 and much less likely to have their condition well managed largely because care can be cost prohibitive. Further, Black Americans are at the most pronounced disadvantage when it comes to access to continuous glucose monitoring 3 . This is one of the reasons why this project was established — to create awareness of healthcare disparities and find holistic solutions to drive improved health outcomes.

"Diabetes is one of the most pressing health issues of our time, particularly for people of color," said Charles Henderson , chief advocacy officer of the American Diabetes Association. "Our Health Equity Now platform serves to tear down the healthcare barriers for historically underserved communities. The program in Columbus will gather real-time data that will help us understand the challenges preventing healthcare equity and uncover solutions to minimize disparities."

ADA's Health Equity Now platform aims to ensure that the more than 122 million Americans living with diabetes and prediabetes 2 , along with millions more at risk for diabetes, have equal access to health resources in cost, care, cure, community and cuisine that can create a future without unjust health disparities.

"At Abbott, we believe that the best health care product is the one that helps the most people," said Badia Boudaiffa, divisional vice president of U.S. commercial operations for Abbott's diabetes business. "That's why this partnership is so important — it will improve health outcomes by building access to affordable, integrated diabetes solutions. There is a strong connection between the health of a community and its overall wellbeing."

Abbott's FreeStyle Libre technology was built with access and affordability in mind to make it broadly available to all people with diabetes. This aligns to Abbott's 2030 Sustainability Plan , which has a clear focus on innovating for access and affordability with the goal of improving the lives of one in every three people on the planet every year by 2030.

"Engaging the community in prevention programing and health awareness campaigns is key to saving lives while strengthening our communities as a whole," said John Gregory , president of NCUS. "We look forward to the participation of members of our community to help strengthen the health and wellbeing of Columbus residents."

"Black individuals across Ohio are twice as likely to die from diabetes compared to non-Hispanic whites," said Dr. Joshua Joseph , M.D., assistant professor of endocrinology, diabetes and metabolism, The Ohio State University . "New technologies such as continuous glucose monitors make diabetes management easier and lead to better control of glucose and may close the disparities in diabetes mortality. Unfortunately, Black populations have lower access and usage of such devices. Thus, approaches like the ADA's Health Equity Now, getting continuous glucose monitors to those who need them most, are critical to advancing diabetes equity."

For information about participating in the community program, contact NCUS at ugotthis@ncusolutions.com .

About the American Diabetes Association:
The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 80 years the ADA has been driving discovery and research to treat, manage and prevent diabetes, while working relentlessly for a cure. We help people with diabetes thrive by fighting for their rights and developing programs, advocacy and education designed to improve their quality of life. Diabetes has brought us together. What we do next will make us Connected for Life. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association ), Twitter ( @AmDiabetesAssn ) and Instagram ( @AmDiabetesAssn ).

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 109,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com , on LinkedIn at www.linkedin.com/company/abbott-/ , on Facebook at www.facebook.com/Abbott and on Twitter @AbbottNews.

Indications and Important Safety Information

FreeStyle Libre 2 system : Failure to use FreeStyle Libre 2 system as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose alarms and readings do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855-632-8658 or https://www.freestyle.abbott/us-en/safety-information.html .

1 The American Diabetes Association's Health Equity Now platform is sponsored by Abbott. All trademarks are the property of their respective owners.
2 https://www.diabetes.org/healthequitynow
3 https://www.diabetes.org/sites/default/files/2021-10/ADA%20CGM%20Utilization%20White%20Paper.pdf

Cision View original content: https://www.prnewswire.com/news-releases/abbott-and-the-american-diabetes-association-launch-first-of-its-kind-community-initiative-in-columbus-ohio-to-advance-access-to-diabetes-care-and-technology-301419877.html

SOURCE Abbott

News Provided by PR Newswire via QuoteMedia

The Conversation (0)

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a global, diversified pharmaceutical company enriching lives through a relentless drive to deliver better health outcomes, issued the following statement in response to a request from the Canadian Investment Regulatory Organization (CIRO

"As previously disclosed, the Company believes that completing the full separation of its subsidiary, Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), makes strategic sense. The Bausch Health Board of Directors authorized management and management of its subsidiary, Bausch + Lomb, to explore a potential sale, which is one of several options being considered to complete the separation. That process is ongoing. No decision has been reached to proceed with any particular transaction, and there can be no assurance that it will result in a transaction.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic announces cash dividend for third quarter of fiscal year 2025

The board of directors of Medtronic plc (NYSE: MDT) on Thursday, December 5, 2024, approved the company's cash dividend for the third quarter of fiscal year 2025 of $0 .70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividend is payable on January 10, 2025 to shareholders of record at the close of business on December 27, 2024 .

About Medtronic
Bold thinking. Bolder actions. We are Medtronic . Medtronic plc , headquartered in Galway , Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 95,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic , visit www.Medtronic.com and follow Medtronic on LinkedIn .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Cardiex Limited (ASX:CDX)

Cardiex Limited


Keep reading...Show less

Bausch Health and Salix in Collaboration with Health Organizations Recognize the Second Annual Opioid-Induced Constipation Awareness Day

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), alongside the U.S. Pain Foundation (USPF), the International Foundation for Gastrointestinal Disorders (IFFGD), and the American Chronic Pain Association (ACPA) have united to recognize today, Thursday, December 5, as the second annual Opioid-Induced Constipation (OIC) Awareness Day. This important day is dedicated to bringing awareness to a commonly-overlooked side effect of opioids. By raising awareness and fostering open conversations, OIC Awareness Day seeks to reduce the stigma surrounding this condition and offer support to the many patients impacted by OIC

"As an organization dedicated to supporting individuals living with pain conditions, we're proud to participate in this year's OIC Awareness Day," said Kathy Sapp, CEO of ACPA. "By increasing awareness and improving communication between healthcare providers, patients, and caregivers, we can make a meaningful difference for those affected by this commonly occurring condition."

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Global Medical Service Robotics Market Project to Exceed $20 Billion in 2024 with Additional Growth Expected

FN Media Group News Commentary - Innovations in robotics technology, including artificial intelligence machine learning, and sensor technology, are enhancing the capabilities of medical robots. These advancements enable more precise surgical procedures, improved rehabilitation processes, and efficient hospital logistics, thus attracting more healthcare facilities to adopt robotic solutions. The market is characterized by a moderate level of merger and acquisition (M&A) activity by the leading players. This is due to several factors, including the desire to expand the business to cater to the growing demand for medical service robots. A report from Grand View Research said that the global medical service robots market size was estimated at USD 20.59 billion in 2024 and is projected to grow at a CAGR of 16.5% from 2025 to 2030. It said: "The growth can be attributed to the introduction of technologically advanced robotic equipment in the healthcare sector and the rise in per capita healthcare spending. Continuous advancements in technology, such as robotic catheter control systems (CCS), data recorders, data analytics, remote navigation, motion sensors, 3D-Imaging, and HD surgical microscopic cameras, are projected to drive industry growth. Furthermore, the introduction of swarm robotics is opening new opportunities for industry. It is a new approach to coordinating multi-robotic systems through swarm intelligence." Active Tech Companies in the markets today include Jeffs' Brands Ltd (NASDAQ: JFBR), Serve Robotics Inc. (NASDAQ: SERV), Symbotic Inc. (NASDAQ: SYM), Microbot Medical Inc. (NASDAQ: MBOT), Medtronic plc (NYSE: MDT).

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×